Łuksza, Marta
Riaz, Nadeem
Makarov, Vladimir
Balachandran, Vinod P.
Hellmann, Matthew D.
Solovyov, Alexander
Rizvi, Naiyer A.
Merghoub, Taha
Levine, Arnold J.
Chan, Timothy A.
Wolchok, Jedd D.
Greenbaum, Benjamin D.
Article History
Received: 22 January 2017
Accepted: 9 October 2017
First Online: 1 November 2017
Competing interests
: M.Ł. has consulted for Merck. V.P.B. has received research funding from Bristol-Myers Squibb. A.J.L. is on the board of directors for Adaptive Biotechnologies and has consulted for Jansen Pharmaceuticals and Merck. T.A.C. is a co-founder of Gritstone Oncology and holds equity. T.A.C. receives grant funding from Bristol Myers Squibb. N.A.R is co-founder and shareholder of Gritstone Oncology. M.D.H. has consulted for Genentech, BMS, Merck, AstraZeneca, Janssen and Novartis. B.D.G. has consulted for Merck.